Multiple sclerosis in pregnancy

CONTINUUM Lifelong Learning in Neurology

Volumn 20, Issue 1, 2014, Pages 42-59

  Coyle, Patricia K ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; FEMALE; HISTORY, 20TH CENTURY; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS;

EID: 84894212725     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000443836.18131.c9     Document Type: Review

References (53)

1. van der Kop ML, Pearce MS, Dahlgren L, et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol 2011;70(1):41-50.
2. Patas K, Broder Engler J, Friese MA, Gold SM. Pregnancy and multiple sclerosis: feto-maternal immune cross talk and its implications for disease activity. J Reprod Immunol 2013;97(1):140-146.
3. Zenclussen AC. Adaptive immune responses during pregnancy. Am J Reprod Immunol 2013;69(4):291-303.
4. Coyle PK. Pregnancy and multiple sclerosis. Neurol Clin 2012;30(3):877-888.
5. Finkelsztejn A, Brooks JB, Paschoal FM Jr, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 2011;118(7):790-797.
6. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69(2):292-302.
7. Alwan S, Yee IM, Dybalski M, et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Mult Scler 2013;19(3):351-358.
8. O'Gorman C, Lin R, Stankovich J, Broadley SA. Modelling genetic susceptibility to multiple sclerosis with family data. Neuroepidemiology 2012;40(1):1-12.
9. Jobin C, Larochelle C, Parpal H, et al. Gender issues in multiple sclerosis: an update. Womens Health (Lond Engl) 2010;6(6): 809-832.
10. McCombe PA, Greer JM. Female reproductive issues in multiple sclerosis. Mult Scler 2013; 19(4):392-402.
11. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998;339(5): 285-291.
12. Paavilainen T, Kurki T, Farkkila M, et al. Lower brain diffusivity in postpartum period compared to late pregnancy: results from a prospective imaging study of multiple sclerosis patients. Neuroradiology 2012;54 (8):823-828.
13. Ponsonby AL, Lucas RM, van der Mei IA, et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event. The Aus Immune Study. Neurology 2012;78(12): 867-874.
14. Lebrun C, Le Page E, Kantarci O, et al. Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. Mult Scler 2012;18 (9):1297-1302.
15. Torkildsen O, Grytten N, Aarseth J, et al. Month of birth as a risk factor for multiple sclerosis: an update. Acta Neurol Scand Suppl 2012;(195):58-62.
16. Dobson R, Giovannoni G, Ramagopalan S. The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry 2013;84(4):427-432.
17. Disanto G, Watson CT, Meier UC, et al. Month of birth and thymic output. JAMA Neurol 2013;70(4):527-528.
18. Mirzaei F, Michels KB, Munger K, et al. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol 2011;70(1): 30-40.
19. Cutter G, Salter A. Got milk? Ann Neurol 2011;70(1):3-4.
20. Salzer J, Hallmans G, Nystrom M, et al. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012;79(21):2140-2145.
21. Verdru P, Theys P, D'Hooghe MB, et al. Pregnancy and multiple sclerosis: the influence on long term disability. Clin Neurol Neurosurg 1994;96(1):38-41.
22. Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995;118(pt 1):253-261.
23. D'hooghe MB, Haentjens P, Nagels G, et al. Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. J Neurol 2012;259(5):855-861.
24. Ramagopalan S, Yee I, Byrnes J, et al. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2012;83(8):793-795.
25. Teter B, Kavak KS, Kolb C, et al. Parity associated with long-term disease progression in women with multiple sclerosis. Presented at: 65th Annual Meeting of the American Academy of Neurology; March 2013; San Diego, CA.
26. Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigliance. Expert Rev Neurother 2013;13(3):251-260.
27. Adapted from Womenshealth.gov. Office on Women's Health, US Department of Health and Human Services. Birth Control Methods. womenshealth.gov/ publications/ourpublications/fact-sheet/birth-controlmethods.pdf. Accessed November 26, 2013.
28. Gnoth C, Godehardt D, Godehardt E, et al. Time to pregnancy: results of the German prospective study and impact on the management of infertility. Hum Reprod 2003;18(9):1959-1966.
29. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler 2013;19(7):835-843.
30. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 2013;260(5):1202-1214.
31. Tomczyk S, Sperling B. Pregnancy outcomes in patients exposed to intramuscular interferon beta-1a (IM IFN-1a) (S30.006). AAN 2013 Annual Meeting.
32. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 2011;17(4):423-430.
33. Lu E, Wang BW, Guimond C, et al. Diseasemodifying drugs for multiple sclerosis in pregnancy. Neurology 2012;79(11): 1130-1135.
34. Hale TW, Siddiqui AA, Baker TE. Transfer of interferon 1a into human breast milk. Breastfeed Med 2012;7(2):123-125.
35. Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. CNS Drugs 2010;24(11):969-976.
36. Cristiano L, Friend S, Bozic C, et al. Evaluation of pregnancy outcomes from the TYSABRI (natalizumab) pregnancy exposure registry. Presented at: 65th Annual Meeting of the American Academy of Neurology; March 2013; San Diego, CA.
37. Haghikia A, Bochum G, Rolfes E, et al. Natalizumab in active MS during pregnancy: efficacy, safety and the consequences for fetal hematopoiesis. Presented at: 65th Annual Meeting of the American Academy of Neurology; March 2013; San Diego, CA.
38. Geissbuhler Y, Butzkueven H, Hernandez-Diaz S, et al. Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya (fingolimod) pregnancy exposure registry in multiple sclerosis. Presented at: 28th Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis.
39. Cassina M, Johnson DL, Robinson K, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012;64(7):2085-2094.
40. Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62(5):1494-1503.
41. Henson LJ, Stuve O, Kieseler B, et al. Pregnancy outcomes from the Teriflunomide clinical development program: retrospective analysis of the Teriflunomide clinical trial database. Presented at: 65th Annual Meeting of the American Academy of Neurology; March 2013; San Diego, CA.
42. Gold R, Bochum G, Phillips T, et al. BG-12 (dimethyl fumarate) and pregnancy: preclinical and clinical data from the clinical development program. Presented at: 65th Annual Meeting of the American Academy of Neurology; March 2013; San Diego, CA.
43. Pasto L, Portaccio E, Ghezzi A, et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol 2012;12:165.
44. Langer-Gould A, Huang SM, Gupta R, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009;66(8): 958-963.
45. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012;5(5): 247-253.
46. Portaccio E, Ghezzi A, Hakiki B, et al. Breastfeeding is not related to postpartum relapse in multiple sclerosis. Neurology 2011;77(2):145-150.
47. Pakpoor J, Disanto G, Lacey MV, et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol 2012; 259(10):2246-2248.
48. Langer-Gould A, Beaber BE. Effects of pregnancy and breastfeeding on the multiple sclerosis disease course. Clin Immunol 2013.doi:10.1016/j.clim.2013.01. 008.
49. Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007;13(7):900-908.
50. Michel L, Foucher Y, Vukusic S, et al. Increased risk of multiple sclerosis relapse after in vitro fertilization. J Neurol Neurosurg Psychiatry 2012;83(8):796-802.
51. Correale J, Farez MF, Ysrraelit MC, et al. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 2012;72(5):682-694.
52. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosiswith the pregnancy hormone estriol. Ann Neurol 2002;52(4):421-428.
53. Vukusic S, El-Etr M, Ionescu I, et al. The POPARTMUS French-Italian multicentric trial of post partum progestin and estriol in multiple sclerosis; final results. Presented at: 28th Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis.